P-49: Study of Cetrorelix in Inhibition of Side Effect of Vincristine Used in Chemotherapy on Germinal Cell Population Seminiferous Tubules of Mice

Background: Infertility problem affects young couples. One of the known causes of spermatogenic disorder is chemotherapy in patients with cancer. Since dividing cells are mainly affected by anticancer drugs, the aim of the present study is to investigate the preventive effect of GnRH antagonist on spermatogenic defect produced by anticancer drug. Materials and Methods: In the present study 30 adult male mice aging 6-8 weeks were used. The mice were divided into 3 equal groups as: control, exp I group and exp II group. In exp I group, A single dose of Vincristine was injected as ip, at 1.5 mg/kg. In and expII group, cetrorelix injection was started one week before vincristine treatment and continued for 3 more weeks. The mice in all groups were sacrificed 3 weeks after the last dose of Cetrorelix injection. Testicular specimens were prepared for LM studies. Results: Microscopic study revealed that in the control group the mean number of sertoli and spermatogonium, were 13.20 ± 2.20 μm, and 47.42 ± 1.96 μm, respectively. In exp I group the mean number of above mentioned cells were 16.8 ± 1.14 μm and 16.53 ± 2.37 μm. In exp II group the mean number of above mentioned cells 10.20 ± 1.13 μm and 36.28 ± 7.98 μm. The data showed the difference between control and exp I group, was significant, but difference between control and exp II group was not. Conclusion: It is concluded that GnRH antagonist administration before cancer treatment could partially prevent the side effect of anticancer drugs.